Pefloxacin MesylateCAS# 70458-95-6 |
- GSK2334470
Catalog No.:BCC4982
CAS No.:1227911-45-6
- BX-912
Catalog No.:BCC1250
CAS No.:702674-56-4
- OSU-03012 (AR-12)
Catalog No.:BCC1255
CAS No.:742112-33-0
- NVP-BAG956
Catalog No.:BCC1813
CAS No.:853910-02-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 70458-95-6 | SDF | Download SDF |
| PubChem ID | 119525 | Appearance | Powder |
| Formula | C18H24FN3O6S | M.Wt | 429.46 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Pefloxacinium mesylate | ||
| Solubility | H2O : ≥ 100 mg/mL (232.85 mM) DMSO : 12.5 mg/mL (29.11 mM; Need ultrasonic) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;methanesulfonic acid | ||
| SMILES | CCN1C=C(C(O)=O)C(=O)c2cc(F)c(cc12)N3CCN(C)CC3.C[S](O)(=O)=O | ||
| Standard InChIKey | HQQSBEDKMRHYME-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C17H20FN3O3.CH4O3S/c1-3-20-10-12(17(23)24)16(22)11-8-13(18)15(9-14(11)20)21-6-4-19(2)5-7-21;1-5(2,3)4/h8-10H,3-7H2,1-2H3,(H,23,24);1H3,(H,2,3,4) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Pefloxacin mesylate is a an antibacterial agent and prevents bacterial DNA replication by inhibiting DNA gyrase (topoisomerse)
Target: DNA gyrase
Pefloxacin is a synthetic chemotherapeutic agent used to treat severe and life-threatening bacterial infections. Pefloxacin is commonly referred to as afluoroquinolone (or quinolone) drug and is a member of the fluoroquinolone class of antibacterials. It is an analog of norfloxacin. It is a synthetic fluoroquinolone, belonging to the 3rd generation of quinolones. Pefloxacin is extensively prescribed in France. Pefloxacin has not been approved for use in the United States.
The bactericidal action of pefloxacin results from interference with the activity of the bacterial enzymes DNA gyrase and topoisomerase IV, which are needed for the transcription and replication of bacterial DNA. DNA gyrase appears to be the primary quinolone target for gram-negative bacteria. Topoisomerase IV appears to be the preferential target in gram-positive organisms. Interference with these two topoisomerases results in strand breakage of the bacterial chromosome, supercoiling, and resealing. As a result DNA replication and transcription is inhibited. References: | |||||
Pefloxacin Mesylate Dilution Calculator
Pefloxacin Mesylate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3285 mL | 11.6425 mL | 23.2851 mL | 46.5701 mL | 58.2126 mL |
| 5 mM | 0.4657 mL | 2.3285 mL | 4.657 mL | 9.314 mL | 11.6425 mL |
| 10 mM | 0.2329 mL | 1.1643 mL | 2.3285 mL | 4.657 mL | 5.8213 mL |
| 50 mM | 0.0466 mL | 0.2329 mL | 0.4657 mL | 0.9314 mL | 1.1643 mL |
| 100 mM | 0.0233 mL | 0.1164 mL | 0.2329 mL | 0.4657 mL | 0.5821 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Pefloxacin mesylate is a an antibacterial agent and prevents bacterial DNA replication by inhibiting DNA gyrase (topoisomerse)
- Pefloxacin
Catalog No.:BCC4231
CAS No.:70458-92-3
- (+)-MK 801
Catalog No.:BCC1288
CAS No.:70449-94-4
- 17alpha-Neriifolin
Catalog No.:BCN4269
CAS No.:7044-31-7
- Dihydrotamarixetin
Catalog No.:BCN4268
CAS No.:70411-27-7
- 4(15),11-Oppositadien-1-ol
Catalog No.:BCN4267
CAS No.:70389-96-7
- Voleneol
Catalog No.:BCN4266
CAS No.:70389-88-7
- 6alpha-Hydroxynidorellol
Catalog No.:BCN4598
CAS No.:70387-38-1
- Lornoxicam
Catalog No.:BCC4425
CAS No.:70374-39-9
- Sideritoflavone
Catalog No.:BCN6689
CAS No.:70360-12-2
- Avobenzone
Catalog No.:BCC4891
CAS No.:70356-09-1
- Methyl Kakuol
Catalog No.:BCN8243
CAS No.:70342-29-9
- 3-Benzoylthiazolidine-2-thione
Catalog No.:BCC8624
CAS No.:70326-37-3
- Norfloxacin
Catalog No.:BCC4688
CAS No.:70458-96-7
- Corymbol
Catalog No.:BCN6617
CAS No.:7047-54-3
- Schizanthine A
Catalog No.:BCN1936
CAS No.:70474-24-7
- Petasinine
Catalog No.:BCN1988
CAS No.:70474-33-8
- Petasinoside
Catalog No.:BCN1989
CAS No.:70474-34-9
- Mitoxantrone HCl
Catalog No.:BCC4924
CAS No.:70476-82-3
- ARP 100
Catalog No.:BCC2370
CAS No.:704888-90-4
- 2'-Hydroxy-5'-methoxyacetophenone
Catalog No.:BCN4270
CAS No.:705-15-7
- 3,5-Dimethoxybenzylalcohol
Catalog No.:BCN3760
CAS No.:705-76-0
- α-Conotoxin PnIA
Catalog No.:BCC5978
CAS No.:705300-84-1
- NS 3763
Catalog No.:BCC7275
CAS No.:70553-45-6
- Aflatrem
Catalog No.:BCN7414
CAS No.:70553-75-2
Study of silver nanoparticles sensitized fluorescence and second-order scattering of terbium(III)-pefloxacin mesylate complex and determination of pefloxacin mesylate.[Pubmed:24892083]
ScientificWorldJournal. 2014;2014:742935.
alpha-Keto acid of Pefloxacin Mesylate (PFLX) can form the complex with Terbium(III). The intramolecular energy from PFLX to Terbium(III) ion takes place when excited, and thus Terbium(III) excited state is formed and then emits the characteristic fluorescence of Terbium(III), locating at 490, 545, 580, and 620 nm. The second-order scattering (SOS) peak at 545 nm also appears for the complex with the exciting wavelength of 273 nm. When the silver nanoparticles are added to the system, the luminescence intensity at 545 nm greatly increased. So, with the adding of nanoparticles to the Terbium(III)-PFLX complex, not only is the intramolecular energy promoted but also the SOS intensity is enhanced. The experimental results show that it is the silver nanoparticles with certain size and certain concentration which can greatly enhance the fluorescence-SOS intensity, and the relative intensity at 545 nm is proportional to the amount of PFLX. Based on this phenomenon, a novel method for the determination of PFLX has been developed and applied to the determination of PFLX in capsule and serum samples.
Superparamagnetic surface molecularly imprinted nanoparticles for water-soluble pefloxacin mesylate prepared via surface initiated atom transfer radical polymerization and its application in egg sample analysis.[Pubmed:22321951]
J Chromatogr A. 2012 Jul 13;1246:15-21.
The novel superparamagnetic surface molecularly imprinted Fe(3)O(4)@MIP nanoparticles for water-soluble Pefloxacin Mesylate (PEF-M) were prepared via surface initiated atom transfer radical polymerization (si-ATRP). The binary mixture of methanol and water was selected as the polar solvents for fabricating PEF-M imprinted MIPs. The Fe(3)O(4)@MIP exhibited high saturation magnetization of 41.4 emu/g leading to the fast separation. The adsorption behaviors indicated that the Fe(3)O(4)@MIP nanoparticles possessed specific recognition and high affinity towards template PEF-M in aqueous media. Moreover, Fe(3)O(4)@MIP nanoparticles were directly used to selectively enrich PEF-M from egg samples. By RP-HPLC analysis, the recoveries of PEF-M were obtained as 92.8-96.5% with relative standard division of 2.4-4.0%.
[Molecular transport mechanism of pefloxacin mesylate binding with transferrin].[Pubmed:23387084]
Yao Xue Xue Bao. 2012 Nov;47(11):1503-10.
The binding mechanism between Pefloxacin Mesylate (PM) and transferrin (Tf) was explored using spectral experiment combined with molecular modeling techniques. The binding parameters and thermodynamic functions of PM-Tf solution system were measured at different temperatures. The effect of PM on molecular conformation of Tf was investigated and the interaction mechanism was also discussed. The results showed that dynamic quenching mechanism occurs with PM binding to Tf. The value of binding distances (r) is low, which indicates the occurrence of energy transfer. The drug had conformational effect on Tf, which resulted in changes of hydrophobic environment of the binding domain in Tf. According to the obtained thermodynamic parameters, the main interaction force between PM and Tf is attributed to hydrophobic bonding. The results of molecular modeling revealed that hydrophobic and hydrogen bonds are main binding forces in the PM-Tf system. These results were in accordance with spectral experiments. The research results have given a better theoretical reference for the study of pharmacological mechanism between protein and quinolone.
Effects of systemic ornidazole, systemic and local compound ornidazole and pefloxacin mesylate on experimental periodontitis in rats.[Pubmed:22367122]
Med Sci Monit. 2012 Mar;18(3):BR95-102.
BACKGROUND: The purpose of the current study is to evaluate the effects of systemic ornidazole (SO) and systemic and local compound ornidazole and Pefloxacin Mesylate (SCOPM/LCOMP) on the inflammatory response associated with rat experimental chronic periodontitis (ECP) in sites with subgingival debridement. MATERIAL/METHODS: Periodontitis was induced in male Sprague-Dawley rats by placing a thin steel ligature around the upper first molars and inoculating them with Porphyromonas gingivalis 381. After the successful induction of the rat ECP, the periodontitis rats were randomly divided into 3 different combined treatment groups: (A) SO with scaling and root planing (SRP); (B) SCOMP with SRP; and (C) LCOMP with SRP. After 2 weeks the effects of the treatments were evaluated based on gingivitis, plaque index, probing pocket depth, aspartate aminotransferase, alveolar bone loss, and hematoxylin-eosin staining of the region around the first molars. RESULTS: After treatment, comparison with ECP was performed. The mean percentage reductions of SBI in SO, SCOPM, and LCOPM were 27.73%, 33.61%, and 58.82%, respectively. Those of PI were 33.20%, 42.80%, and 60.00%; those of PPD were 48.66%, 55.70%, and 72.48%; those of GCF-AST were 41.64%, 49.03%, and 66.42%; and those of ABL were 41.19%, 43.63%, and 54.47%, respectively. The inflammatory score of H&E showed median scores of 2.5, 1.75, 1.63, and 0.95 for ECP, SO, SCOMP, and LCOMP, respectively. All 3 treatment groups exhibited significantly reduced inflammation indicators (P<0.05). Of the 3, group C was the most effective (P<0.05). CONCLUSIONS: Although all the combined treatment groups responded to therapy with significant resolution of the infection, adjunctive LCOMP therapy is more effective for periodontitis.
